KIN - Kindred Biosciences, Inc.
| Previous Close | 6.97 |
| Open | 7.04 |
| Bid | 6.70 x 800 |
| Ask | 10.90 x 900 |
| Day's Range | 7.04 - 7.33 |
| 52 Week Range | 5.96 - 15.20 |
| Volume | 97,453 |
| Avg. Volume | 183,319 |
| Market Cap | 284.364M |
| Beta (3Y Monthly) | 0.14 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.63 |
| Earnings Date | Feb 27, 2018 - Mar 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.53 |
- Simply Wall St.
The Kindred Biosciences (NASDAQ:KIN) Share Price Has Gained 88% And Shareholders Are Hoping For More
While Kindred Biosciences, Inc. (NASDAQ:KIN) shareholders are probably generally happy, the stock hasn't had...
- Thomson Reuters StreetEvents
Edited Transcript of KIN earnings conference call or presentation 1-Aug-19 8:30pm GMT
Q2 2019 Kindred Biosciences Inc Earnings Call
Motley FoolKindred Biosciences (KIN) Q2 2019 Earnings Call Transcript
KIN earnings call for the period ending June 30, 2019.
- Zacks
Kindred Biosciences (KIN) Reports Q2 Loss, Lags Revenue Estimates
Kindred Bio (KIN) delivered earnings and revenue surprises of -2.78% and -37.39%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Kindred Biosciences Announces Second Quarter 2019 Financial Results and Unveils Positive Results from Pilot Efficacy Study of Parvovirus Monoclonal Antibody
SAN FRANCISCO, Aug. 1, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the second quarter ended June 30, 2019 and provided updates on its programs, including positive results from a pilot efficacy study of its previously undisclosed parvovirus monoclonal antibody. For the second quarter 2019, KindredBio reported net product revenues of $1.2 million and a net loss of $14.3 million, or $0.37 per share. For the first six months of 2019, net product revenues were $1.8 million and the net loss was $30.4 million, or $0.79 per share.
- PR Newswire
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of its Interleukin-31 Monoclonal Antibody for the Treatment of Atopic Dermatitis in Dogs
- Achieved rapid and dramatic reduction in pruritus (itch) and CADESI score versus placebo. - Call to discuss study results at 8:30 a.m. Eastern time today. SAN FRANCISCO, July 29, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pilot effectiveness study of KIND-016, a fully caninized, high-affinity monoclonal antibody targeting interleukin-31 (IL-31), for the treatment of atopic dermatitis in dogs.
- PR Newswire
Kindred Biosciences to Announce Second Quarter 2019 Financial Results
SAN FRANCISCO, July 16, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will release its second quarter 2019 financial results on August 1, 2019, after the market close. The Company will host a conference call at 4:30 p.m. Eastern time/1:30 p.m. Pacific time that day. Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets.
- Insider Monkey
Here’s What Hedge Funds Think About Kindred Biosciences Inc (KIN)
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]
- TheStreet.com
A Handful of Small Biotechs That Make for Merger Chatter
The biotech sector continues to have a very good week, although some profit taking did take place in the second half of trading Thursday even as the S&P 500 hit an all-time high. On Wednesday we considered a couple mid-cap biotech names that would make logical buyout candidates should we see an uptick in merger-and-acquisition (M&A) activity in the second half of the year. Kindred has just one approved product but several in development.
- PR Newswire
Kindred Biosciences to Participate in the B. Riley FBR Institutional Investor Conference, Stifel 2019 Dental & Veterinary Conference and 9th Annual LD Micro Invitational
SAN FRANCISCO , May 13, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in ...
- Motley Fool
Kindred Biosciences (KIN) Q1 2019 Earnings Call Transcript
KIN earnings call for the period ending March 31, 2019.
- Thomson Reuters StreetEvents
Edited Transcript of KIN earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Kindred Biosciences Inc Earnings Call
- Zacks
Kindred Biosciences (KIN) Reports Q1 Loss, Misses Revenue Estimates
Kindred Bio (KIN) delivered earnings and revenue surprises of 0.00% and -73.62%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Kindred Bio: 1Q Earnings Snapshot
On a per-share basis, the Burlingame, California-based company said it had a loss of 42 cents. The biopharmaceutical company posted revenue of $515,000 in the period. Kindred Bio shares have dropped 18% ...
- PR Newswire
Kindred Biosciences Announces First Quarter 2019 Financial Results
SAN FRANCISCO, May 9, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2019 and provided updates on its programs. For the first quarter 2019, KindredBio reported net product revenues of $0.5 million and a net loss of $16.1 million, or $0.42 per share. While net product revenues were lower versus the fourth quarter, sales of Mirataz from distributors to veterinary clinics increased quarter-over-quarter.
- Simply Wall St.
Do Institutions Own Kindred Biosciences, Inc. (NASDAQ:KIN) Shares?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in Kindred Biosciences, Inc. (NASDAQ:KIN) have power over the company...
- PR Newswire
Kindred Biosciences to Announce First Quarter 2019 Financial Results
SAN FRANCISCO, April 25, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its first quarter 2019 financial results on May 9, 2019 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day. Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets.
- Thomson Reuters StreetEvents
Edited Transcript of KIN earnings conference call or presentation 6-Mar-19 9:30pm GMT
Q4 2018 Kindred Biosciences Inc Earnings Call
- Simply Wall St.
Kindred Biosciences, Inc. (NASDAQ:KIN) Has Attractive Fundamentals
Kindred Biosciences, Inc. (NASDAQ:KIN) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case ofRead More...
Motley FoolKindred Biosciences Inc (KIN) Q4 2018 Earnings Conference Call Transcript
KIN earnings call for the period ending December 31, 2018.
- PR Newswire
Kindred Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results
SAN FRANCISCO, March 6, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2018 and provided updates on its programs. For the fourth quarter 2018, KindredBio reported net product revenues of $1.3 million and a net loss of $15.4 million, or $0.46 per share. For the full year 2018, net product revenues were $2.0 million and the net loss was $49.7 million, or $1.60 per share.
- PR Newswire
Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial Results
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, March 6, 2019 SAN FRANCISCO , Feb. 19, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...
- PR Newswire
Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare Conference
SAN FRANCISCO , Feb. 13, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the ...
- PR Newswire
Kindred Group plc - Year end report January - December 2018 (Unaudited)
Underlying EBITDA for the fourth quarter of 2018 was GBP 58.8 (74.5) million, and GBP 203.7 (185.0) million for the full year 2018. Profit before tax for the fourth quarter of 2018 amounted to GBP 45.0 (55.9) million, and GBP 149.5 (132.0) million for the full year 2018.
